Metformin News and Research RSS Feed - Metformin News and Research

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.
Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%. [More]
Labelling people as pre-diabetic is drastically premature measure with no medical value

Labelling people as pre-diabetic is drastically premature measure with no medical value

Labelling people with moderately high blood sugar as pre-diabetic is a drastically premature measure with no medical value and huge financial and social costs, say researchers from UCL and the Mayo Clinic, Minnesota. [More]
Medical treatment guidelines for diabetes

Medical treatment guidelines for diabetes

Medical treatment guidelines are suggestions that international organizations such as the American Diabetes Association, the European Society for the Study of Diabetes and the American Association of Clinical Endocrinologists, used to set the tone in the control of the disease and how to apply a better therapy, depending on the physical condition of the person. [More]
Continuation of metformin after cirrhosis diagnosis improves survival rates in diabetes patients

Continuation of metformin after cirrhosis diagnosis improves survival rates in diabetes patients

Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. [More]
Mayo Clinic study: Reversing current thought on treatment of cirrhotic patients with type 2 diabetes

Mayo Clinic study: Reversing current thought on treatment of cirrhotic patients with type 2 diabetes

Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. The study found that the continuation of metformin after a cirrhosis diagnosis improved survival rates among diabetes patients. [More]
U of MD researchers to use $3.7 million NIH grant to develop novel method to treat monogenic diabetes

U of MD researchers to use $3.7 million NIH grant to develop novel method to treat monogenic diabetes

The National Institutes of Health has awarded a four-year, $3.7 million grant to researchers at the University of Maryland School of Medicine to develop a personalized medicine program to help doctors diagnose and treat monogenic diabetes - a form of diabetes caused by a mutation in a single gene. [More]
Type 2 diabetes Patients who take metformin plus insulin at higher risk for heart disease, death

Type 2 diabetes Patients who take metformin plus insulin at higher risk for heart disease, death

Patients with type 2 diabetes who take a combination of metformin plus insulin may be at higher risk for cardiovascular disease and death compared with those who take a combination of metformin plus sulfonylurea, according to a new study funded by the Agency for Healthcare Research and Quality that appears in the June 11 issue of JAMA. [More]
Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

In the largest study of its kind published to date, an international team of researchers in Mexico and the United States has discovered a strong genetic risk factor for type 2 diabetes that primarily affects Latin American patients, but is rare elsewhere. [More]
FDA grants orphan drug designation to EffRx Pharmaceuticals' EX404 for treatment of PCOS

FDA grants orphan drug designation to EffRx Pharmaceuticals' EX404 for treatment of PCOS

EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS). [More]
Metformin drug slows ageing and increases lifespan

Metformin drug slows ageing and increases lifespan

A study by Belgian doctoral researcher Wouter De Haes (KU Leuven) and colleagues provides new evidence that metformin, the world's most widely used anti-diabetic drug, slows ageing and increases lifespan. [More]
NCI awards 'provocative questions' grants to Jackson lab researchers

NCI awards 'provocative questions' grants to Jackson lab researchers

Jackson Laboratory Assistant Professors Jennifer Trowbridge, Ph.D., and Chengkai Dai, M.D., Ph.D., have each received new federal research grants through a funding mechanism designed to address "provocative questions" about cancer set out by the National Cancer Institute (NCI). [More]
Commonly used diabetes medications may also have positive effects against cancer cell proliferation

Commonly used diabetes medications may also have positive effects against cancer cell proliferation

One of the most commonly used medications to control diabetes may also have positive effects against cancer cell proliferation, as show in research done at the Center for Research and Advanced Studies (CINVESTAV) in Mexico. [More]
European Commission grants Marketing Authorization for empagliflozin for treatment of type 2 diabetes

European Commission grants Marketing Authorization for empagliflozin for treatment of type 2 diabetes

The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company. [More]
Combination of metformin and rapamycin shows potential in treating aging and related diseases

Combination of metformin and rapamycin shows potential in treating aging and related diseases

A proven approach to slow the aging process is dietary restriction, but new research in the Linus Pauling Institute at Oregon State University helps explain the action of a drug that appears to mimic that process - rapamycin. [More]
Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. [More]
Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates. [More]
Factors that lead to diabetes contribute to low milk supply in some new mothers

Factors that lead to diabetes contribute to low milk supply in some new mothers

New studies provide fresh evidence that the same factors that lead to diabetes contribute to low milk supply in some new mothers. [More]
European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control. [More]
FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%. [More]